Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
- 11k Downloads
The consensus algorithm for the medical management of type 2 diabetes was published in August 2006 with the expectation that it would be updated, based on the availability of new interventions and new evidence to establish their clinical role. The authors continue to endorse the principles used to develop the algorithm and its major features. We are sensitive to the risks of changing the algorithm cavalierly or too frequently, without compelling new information. An update to the consensus algorithm published in January 2008 specifically addressed safety issues surrounding the thiazolidinediones. In this revision, we focus on the new classes of medications that now have more clinical data and experience.
KeywordsMetformin Glycaemic Control HbA1c Level Lifestyle Intervention Consensus Algorithm
Action to Control Cardiovascular Risk in Diabetes
Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation
dipeptidyl peptidase 4
glucose-dependent insulinotropic peptide
glucagon-like peptide 1
self-monitoring of blood glucose
University Group Diabetes Program
UK Prospective Diabetes Study
The epidemic of type 2 diabetes mellitus and the recognition that achieving specific glycaemic goals can substantially reduce morbidity have made the effective treatment of hyperglycaemia a top priority [1, 2, 3]. While the management of hyperglycaemia, the hallmark metabolic abnormality associated with type 2 diabetes, has historically taken centre stage in the treatment of diabetes, therapies directed at other coincident features, such as dyslipidaemia, hypertension, hypercoagulability, obesity and insulin resistance, have also been a major focus of research and therapy. Maintaining glycaemic levels as close to the non-diabetic range as possible has been demonstrated to have a powerful beneficial effect on diabetes-specific microvascular complications, including retinopathy, nephropathy and neuropathy, in the setting of type 1 diabetes [4, 5]; in type 2 diabetes, more intensive treatment strategies have likewise been demonstrated to reduce microvascular complications [6, 7, 8]. Intensive glycaemic management resulting in lower HbA1c levels has also been shown to have a beneficial effect on cardiovascular disease (CVD) complications in type 1 diabetes [9, 10]; however, current studies have failed to demonstrate a beneficial effect of intensive diabetes therapy on CVD in type 2 diabetes [11, 12, 13].
The development of new classes of blood glucose-lowering medications to supplement the older therapies, such as lifestyle-directed interventions, insulin, sulfonylureas and metformin, has increased the number of treatment options available for type 2 diabetes. Whether used alone or in combination with other blood glucose-lowering interventions, the increased number of choices available to practitioners and patients has heightened uncertainty regarding the most appropriate means of treating this widespread disease . Although numerous reviews on the management of type 2 diabetes have been published in recent years [15, 16, 17], practitioners are often left without a clear pathway of therapy to follow. We developed the following consensus approach to the management of hyperglycaemia in the non-pregnant adult to help guide healthcare providers in choosing the most appropriate interventions for their patients with type 2 diabetes.
The guidelines and algorithm that follow are derived from two sources. One source is the clinical trials that address the effectiveness and safety of the different modalities of therapy. Here, the writing group reviewed a wide variety of studies related to the use of drugs as monotherapy or in combination to lower glycaemia. Unfortunately, the paucity of high-quality evidence in the form of well-controlled clinical trials that directly compare different diabetes treatment regimens remains a major impediment to recommending one class of drugs, or a particular combination of therapies, over another.
The second source of material that informed our recommendations was clinical judgement, that is, our collective knowledge and clinical experience, which takes into account benefits, risks and costs in the treatment of diabetes. As in all clinical decision-making, an evidence-based review of the literature must also be supplemented by value judgements, where the benefits of treatment are weighed against risks and costs in a subjective fashion. While we realise that others may have different judgements, we believe that the recommendations made in this new iteration of our treatment algorithm will guide therapy and result in improved glycaemic control and health status over time.
Glycaemic goals of therapy
Controlled clinical trials, such as the DCCT  and the Stockholm Diabetes Study in type 1 diabetes , and the UK Prospective Diabetes Study (UKPDS) [6, 7] and Kumamoto study  in type 2 diabetes, have helped to establish the glycaemic goals of therapy that result in improved long-term outcomes. The clinical trials, in concert with epidemiological data [18, 19], support decreasing glycaemia as an effective means of reducing long-term microvascular and neuropathic complications. The most appropriate target levels for blood glucose, on a day-to-day basis, and HbA1c, as an index of chronic glycaemia, have not been systematically studied. However, both the DCCT  and the UKPDS [6, 7] had as their goals the achievement of glycaemic levels in the non-diabetic range. Neither study was able to maintain HbA1c levels in the non-diabetic range in their intensive treatment groups, achieving mean levels over time of ~7%, which is 4 SDs above the non-diabetic mean.
The most recent glycaemic goal recommended by the American Diabetes Association, selected on the basis of practicality and the projected reduction in complications over time, is, in general, an HbA1c level of <7% . The most recent glycaemic goal set by the International Diabetes Federation is an HbA1c level of <6.5%. The upper limit of the non-diabetic range is 6.1% (mean HbA1c level of 5% + 2 SD) with the DCCT/UKPDS-standardised assay, which has been promulgated through the National Glycohemoglobin Standardization Program (NGSP) and adopted by the vast majority of commercially available assays . Several recent clinical trials have aimed for HbA1c levels ≤6.5% with a variety of interventions [11, 12]. The results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, which had the primary objective of decreasing CVD with interventions aimed at achieving an HbA1c level of <6.0% vs interventions aimed at achieving an HbA1c level of <7–7.9%, showed excess CVD mortality in the intensive treatment group . Results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial and the Veterans Affairs Diabetes Trial, both of which had different interventions and study populations than ACCORD, did not demonstrate any excess total or CVD mortality with intensive regimens that achieved HbA1c levels comparable to the 6.5% in ACCORD [12, 13]. However, none of the studies has demonstrated a benefit of intensive glycaemic control on their primary CVD outcomes. Our consensus is that an HbA1c level of ≥7% should serve as a call to action to initiate or change therapy with the goal of achieving an HbA1c level of <7%. We are mindful that this goal is not appropriate or practical for some patients, and clinical judgement based on the potential benefits and risks of a more intensified regimen needs to be applied for every patient. Factors such as life expectancy, risk of hypoglycaemia and the presence of CVD need to be considered for every patient before intensifying the therapeutic regimen.
Assiduous attention to abnormalities other than hyperglycaemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications. Readers are referred to published guidelines for a discussion of the rationale and goals of therapy for the non-glycaemic risk factors, as well as recommendations on how to achieve them [1, 21, 22].
Principles in selecting antihyperglycaemic interventions
Our choice of specific antihyperglycaemic agents is predicated on their effectiveness in lowering glucose, extraglycaemic effects that may reduce long-term complications, safety profiles, tolerability, ease-of-use and expense.
Effectiveness in lowering glycaemia
Summary of glucose-lowering interventions
Expected decrease in HbA1c (%) with monotherapy
Tier 1: Well-validated core
Step 1: Initial therapy
Lifestyle to decrease weight and increase activity
Insufficient for most within first year
GI side effects, contraindicated with renal insufficiency
Step 2: Additional therapy
No dose limit, rapidly effective, improved lipid profile
One to four injections daily, monitoring, weight gain, hypoglycaemia, analogues are expensive
Weight gain, hypoglycaemia (especially with glibenclamide or chlorpropamide)
Tier 2: Less well-validated
Improved lipid profile (pioglitazone), potential decrease in MI (pioglitazone)
Fluid retention, CHF, weight gain, bone fractures, expensive, potential increase in MI (rosiglitazone)
Two injections daily, frequent GI side effects, long-term safety not established, expensive
Frequent GI side effects, three times/day dosing, expensive
Weight gain, three times/day dosing, hypoglycaemia, expensive
Three injections daily, frequent GI side effects, long-term safety not established, expensive
Long-term safety not established, expensive
Non-glycaemic effects of medications
In addition to variable effects on glycaemia, specific effects of individual therapies on CVD risk factors, such as hypertension or dyslipidaemia, were also considered important. We also included the effects of interventions that may benefit or worsen the prospects for long-term glycaemic control in our recommendations. Examples of these would be changes in body mass, insulin resistance, or insulin secretory capacity in type 2 diabetic patients.
Choosing specific diabetes interventions and their roles in treating type 2 diabetes
Numerous reviews have focused on the characteristics of the specific diabetes interventions listed below [25, 26, 27, 28, 29, 30, 31, 32, 33, 34]. In addition, meta-analyses and reviews have summarised and compared the glucose-lowering effectiveness and other characteristics of the medications [35, 36, 37]. The aim here is to provide enough information to justify the choices of medications, the order in which they are recommended and the use of combinations of therapies. Unfortunately, there is a dearth of high-quality studies that provide head-to-head comparisons of the ability of the medications to achieve the currently recommended glycaemic levels. The authors highly recommend that such studies be conducted. However, even in the absence of rigorous, comprehensive studies that directly compare the efficacy of all available glucose-lowering treatments and their combinations, we feel that there are enough data regarding the characteristics of the individual interventions to provide the guidelines below.
An important intervention that is likely to improve the probability that a patient will have better long-term control of diabetes is to make the diagnosis early, when the metabolic abnormalities of diabetes are usually less severe. Lower levels of glycaemia at the time of initial therapy are associated with lower HbA1c levels over time and decreased long-term complications .
The major environmental factors that increase the risk of type 2 diabetes are overnutrition and a sedentary lifestyle, with consequent overweight and obesity [39, 40]. Not surprisingly, interventions that reverse or improve these factors have been demonstrated to have a beneficial effect on control of glycaemia in established type 2 diabetes . Unfortunately, the high rate of weight regain has limited the role of lifestyle interventions as an effective means of controlling glycaemia in the long term. The most convincing long-term data indicating that weight loss effectively lowers glycaemia have been generated in the follow-up of type 2 diabetic patients who have had bariatric surgery. In this setting, with a mean sustained weight loss of >20 kg, diabetes is virtually eliminated [42, 43, 44, 45]. In addition to the beneficial effects of weight loss on glycaemia, weight loss and exercise improve coincident CVD risk factors, such as blood pressure and atherogenic lipid profiles, and ameliorate other consequences of obesity [41, 46, 47]. There are few adverse consequences of such lifestyle interventions other than difficulty in incorporating them into usual lifestyle and sustaining them, and the usually minor musculoskeletal injuries and potential problems associated with neuropathy, such as foot trauma and ulcers, that may occur as a result of increased activity. Theoretically, effective weight loss, with its pleiotropic benefits, safety profile and low cost, should be the most cost-effective means of controlling diabetes, if it could be achieved and maintained over the long term.
Given these beneficial effects, which are usually seen rapidly—within weeks to months—and often before there has been substantial weight loss , a lifestyle intervention programme to promote weight loss and increase activity levels should, with rare exceptions, be included as part of diabetes management. Weight loss of as little as 4 kg will often ameliorate hyperglycaemia. However, the limited long-term success of lifestyle programmes to maintain glycaemic goals in patients with type 2 diabetes suggests that the large majority of patients will require the addition of medications over the course of their diabetes.
The characteristics of currently available glucose-lowering interventions, when used as monotherapy, are summarised in Table 1. The glucose-lowering effectiveness of individual therapies and combinations demonstrated in clinical trials is predicated not only on the intrinsic characteristics of the intervention, but also on the duration of diabetes, baseline glycaemia, previous therapy and other factors. A major factor in selecting a class of drugs, or a specific medication within a class, to initiate therapy or when changing therapy, is the ambient level of glycaemic control. When levels of glycaemia are high (e.g. HbA1c > 8.5%), classes with greater and more rapid glucose-lowering effectiveness, or potentially earlier initiation of combination therapy, are recommended; however, patients with recent-onset diabetes often respond adequately to less intensive interventions than those with longer term disease . When glycaemic levels are closer to the target levels (e.g. HbA1c < 7.5%), medications with lesser potential to lower glycaemia and/or a slower onset of action may be considered.
Obviously, the choice of glycaemic goals and the medications used to achieve them must be individualised for each patient, balancing the potential for lowering HbA1c and anticipated long-term benefit with specific safety issues, as well as other characteristics of regimens, including side effects, tolerability, ease-of-use, long-term adherence, expense and the non-glycaemic effects of the medications. Type 2 diabetes is a progressive disease characterised by worsening glycaemia; higher doses and additional medications are required over time if treatment goals are to be met.
In most of the world, metformin is the only biguanide available. Its major effect is to decrease hepatic glucose output and lower fasting glycaemia. Typically, metformin monotherapy will lower HbA1c levels by ~1.5 percentage points [27, 49]. It is generally well tolerated, with the most common adverse effects being gastrointestinal. Metformin monotherapy is not usually accompanied by hypoglycaemia, and has been used safely, without causing hypoglycaemia, in patients with pre-diabetic hyperglycaemia . Metformin interferes with vitamin B12 absorption, but is very rarely associated with anaemia . The major non-glycaemic effect of metformin is either weight stability or modest weight loss, in contrast to many of the other blood glucose-lowering medications. The UKPDS demonstrated a beneficial effect of metformin therapy on CVD outcomes , which needs to be confirmed. Renal dysfunction is considered a contraindication to metformin use because it may increase the risk of lactic acidosis, an extremely rare (less than one case per 100,000 treated patients) but potentially fatal complication . However, recent studies have suggested that metformin is safe unless the estimated glomerular filtration rate falls to <30 ml/min .
Sulfonylureas lower glycaemia by enhancing insulin secretion. In terms of efficacy, they appear to be similar to metformin, lowering HbA1c levels by ~1.5 percentage points [26, 49]. The major adverse side effect is hypoglycaemia, which can be prolonged and life-threatening, but such episodes, characterised by a need for assistance, coma or seizure, are infrequent. However, severe episodes are relatively more frequent in the elderly. Chlorpropamide and glibenclamide (known as glyburide in the USA and Canada), are associated with a substantially greater risk of hypoglycaemia than other second-generation sulfonylureas (gliclazide, glimepiride, glipizide, and their extended formulations), which are preferable (Table 1) [53, 54]. In addition, weight gain of ~2 kg is common following the initiation of sulfonylurea therapy. Although the onset of the glucose-lowering effect of sulfonylurea monotherapy is relatively rapid compared with, for example, the thiazolidinediones (TZDs), maintenance of glycaemic targets over time is not as good as monotherapy with a TZD or metformin . Sulfonylurea therapy was implicated as a potential cause of increased CVD mortality in the University Group Diabetes Program (UGDP) study . Concerns raised by the UGDP that sulfonylureas, as a drug class, may increase CVD mortality in type 2 diabetes were not substantiated by the UKPDS or ADVANCE study [6, 12]. The glycaemic benefits of sulfonylureas are nearly fully realised at half-maximal doses and higher doses should generally be avoided.
Like the sulfonylureas, the glinides stimulate insulin secretion, although they bind to a different site within the sulfonylurea receptor . They have a shorter circulating half-life than the sulfonylureas and must be administered more frequently. Of the two glinides currently available in the USA, repaglinide is almost as effective as metformin or the sulfonylureas, decreasing HbA1c levels by ~1.5 percentage points. Nateglinide is somewhat less effective in lowering HbA1c than repaglinide when used as monotherapy or in combination therapy [57, 58]. The risk of weight gain is similar to that for the sulfonylureas, but hypoglycaemia may be less frequent, at least with nateglinide, than with some sulfonylureas [58, 59].
α-Glucosidase inhibitors reduce the rate of digestion of polysaccharides in the proximal small intestine, primarily lowering postprandial glucose levels without causing hypoglycaemia. They are less effective in lowering glycaemia than metformin or the sulfonylureas, reducing HbA1c levels by 0.5–0.8 percentage points . Since carbohydrate is absorbed more distally, malabsorption and weight loss do not occur; however, increased delivery of carbohydrate to the colon commonly results in increased gas production and gastrointestinal symptoms. In clinical trials, 25–45% of participants have discontinued α-glucosidase inhibitor use as a result of this side effect [29, 60].
One clinical trial examining acarbose as a means of preventing the development of diabetes in high-risk individuals with impaired glucose tolerance showed an unexpected reduction in severe CVD outcomes . This potential benefit of α-glucosidase inhibitors needs to be confirmed.
Thiazolidinediones (TZDs or glitazones) are peroxisome proliferator-activated receptor γ modulators; they increase the sensitivity of muscle, fat and liver to endogenous and exogenous insulin (‘insulin sensitisers’) . The data regarding the blood glucose-lowering effectiveness of TZDs when used as monotherapy have demonstrated a 0.5–1.4 percentage point decrease in HbA1c. The TZDs appear to have a more durable effect on glycaemic control, particularly compared with sulfonylureas . The most common adverse effects with TZDs are weight gain and fluid retention, with peripheral oedema and a twofold increased risk for congestive heart failure [61, 62]. There is an increase in adiposity, largely subcutaneous, with some reduction in visceral fat shown in some studies. The TZDs either have a beneficial (pioglitazone) or neutral (rosiglitazone) effect on atherogenic lipid profiles [63, 64]. Several meta-analyses have suggested a 30–40% relative increase in risk for myocardial infarction [65, 66] with rosiglitazone. On the other hand, the Prospective Pioglitazone Clinical Trial in macrovascular events (PROactive) demonstrated no significant effects of pioglitazone compared with placebo on the primary CVD outcome (a composite of all-cause mortality, non-fatal and silent myocardial infarction, stroke, major leg amputation, acute coronary syndrome, coronary artery bypass graft or percutaneous coronary intervention, and leg revascularisation) after 3 years of follow-up . Pioglitazone was associated with a 16% reduction in death, myocardial infarction and stroke—a controversial secondary endpoint reported to have marginal statistical significance . Meta-analyses have supported a possible beneficial effect of pioglitazone on CVD risk . Although the data are less than conclusive for a CVD risk with rosiglitazone or a CVD benefit with pioglitazone, we have previously advised  caution in using either TZD, on the basis that they are both associated with increased risks of fluid retention and congestive heart failure, and an increased incidence of fractures in women, and perhaps in men [55, 61, 62, 70]. Although the meta-analyses discussed above are not conclusive regarding the potential cardiovascular risk associated with rosiglitazone, given that other options are now recommended, the consensus group members unanimously advised against using rosiglitazone. Currently, in the USA, the TZDs are approved for use in combination with metformin, sulfonylureas, glinides and insulin.
Glucagon-like peptide 1 agonists (exenatide)
Glucagon-like peptide 1 (GLP-1) 7–37, a naturally occurring peptide produced by the L cells of the small intestine, potentiates glucose-stimulated insulin secretion. Exendin-4 has homology with the human GLP-1 sequence, but has a longer circulating half-life. It binds avidly to the GLP-1 receptor on the pancreatic beta cell and augments glucose-mediated insulin secretion . Synthetic exendin-4 (exenatide) was approved for use in the USA in 2005 and is administered twice per day by subcutaneous injection. Although there are less published data on this new compound than the other blood glucose-lowering medications, exendin-4 appears to lower HbA1c levels by 0.5–1 percentage points, mainly by lowering postprandial blood glucose levels [78, 79, 80, 81]. Exenatide also suppresses glucagon secretion and slows gastric motility. It is not associated with hypoglycaemia, but causes a relatively high frequency of gastrointestinal disturbances, with 30–45% of treated patients experiencing one or more episodes of nausea, vomiting or diarrhoea [78, 79, 80, 81]. These side effects tend to abate over time. In published trials, exenatide is associated with weight loss of ~2–3 kg over 6 months, some of which may be a result of its gastrointestinal side effects. Recent reports have suggested a risk for pancreatitis associated with use of GLP agonists; however, the number of cases is very small and whether the relationship is causal or coincidental is not clear at this time. Currently, exenatide is approved for use in the USA with sulfonylurea, metformin and/or a TZD. Several other GLP-1 agonists and formulations are under development.
Amylin agonists (pramlintide)
Pramlintide is a synthetic analogue of the beta cell hormone amylin. It is administered subcutaneously before meals and slows gastric emptying, inhibits glucagon production in a glucose-dependent fashion, and predominantly decreases postprandial glucose excursions . In clinical studies, HbA1c has been decreased by 0.5–0.7 percentage points . The major clinical side effects of this drug are gastrointestinal in nature. Approximately 30% of treated participants in the clinical trials have developed nausea, but this side effect tends to abate with time on therapy. Weight loss associated with this medication is ~1–1.5 kg over 6 months; as with exenatide, some of the weight loss may be the result of gastrointestinal side effects. Currently, pramlintide is approved for use in the USA only, as adjunctive therapy with regular insulin or rapid-acting insulin analogues.
Dipeptidyl peptidase 4 inhibitors
GLP-1 and glucose-dependent insulinotropic peptide (GIP), the main insulinotropic peptides of intestinal origin (incretins), are rapidly degraded by dipeptidyl peptidase 4 (DPP-4). DPP-4 is a member of a family of cell membrane proteins that are expressed in many tissues, including immune cells . DPP-4 inhibitors are small molecules that enhance the effects of GLP-1 and GIP, increasing glucose-mediated insulin secretion and suppressing glucagon secretion. [83, 84]. The first oral DPP-4 inhibitor, sitagliptin, was approved by the Food and Drug Administration in October 2006 for use as monotherapy or in combination with metformin or TZDs. Another DPP-4 inhibitor, vildagliptin, was approved in Europe in February 2008, and several other compounds are under development. In clinical trials performed to date, DPP-4 inhibitors lower HbA1c levels by 0.6–0.9 percentage points and are weight neutral and relatively well tolerated [83, 84]. They do not cause hypoglycaemia when used as monotherapy. A fixed-dose combination pill with metformin is available. The potential for this class of compounds to interfere with immune function is of concern; an increase in upper respiratory infections has been reported .
How to initiate diabetes therapy and advance interventions
Except in rare circumstances, such as diabetic ketoacidosis or patients who are extremely catabolic or hyperosmolar or who are unable to hydrate themselves adequately (see Special considerations/patients below), hospitalisation is not required for initiation or adjustment of therapy. The patient is the key player in the diabetes care team and should be trained and empowered to adjust medications with the guidance of healthcare professionals to achieve glycaemic goals and to prevent and treat hypoglycaemia. Many patients may be managed effectively with monotherapy; however, the progressive nature of the disease will require the use of combination therapy in many, if not most, patients over time, to achieve and maintain glycaemia in the target range.
The measures of glycaemia that are initially targeted on a day-to-day basis are fasting and preprandial glucose levels. Self-monitoring of blood glucose (SMBG) is an important element in adjusting or adding new interventions and, in particular, in titrating insulin doses. The need for and number of required SMBG measurements are not clear  and are dependent on the medications used. Oral glucose-lowering regimens that do not include sulfonylureas or glinides, and are therefore not likely to cause hypoglycaemia, usually do not require SMBG.  However, SMBG may be used to determine whether therapeutic blood glucose targets are being achieved and for adjustment of treatment regimens without requiring the patient to have laboratory-based blood glucose testing. Insulin therapy requires more frequent monitoring.
The levels of plasma or capillary glucose (most meters that measure fingerstick capillary samples are adjusted to provide values equivalent to plasma glucose) that should result in long-term glycaemia in the non-diabetic target range, as measured by HbA1c, are fasting and preprandial levels between 3.9 and 7.2 mmol/l (70 and 130 mg/dl). If HbA1c levels remain above the desired target despite preprandial levels that are in range, postprandial levels, usually measured 90–120 min after a meal, may be checked. They should be <10 mmol/l (180 mg/dl) to achieve HbA1c levels in the target range.
Attempts to achieve target glycaemic levels with regimens including sulfonylureas or insulin may be associated with modest hypoglycaemia, with glucose levels in the 3.1–3.9 mmol/l (55–70 mg/dl) range. These episodes are generally well tolerated, easily treated with oral carbohydrate, such as glucose tablets or 120–180 ml (4–6 oz) of juice or non-diet soda, and rarely progress to more severe hypoglycaemia, including loss of consciousness or seizures.
- Tier 1:
well-validated core therapies
These interventions represent the best established and most effective and cost-effective therapeutic strategy for achieving the target glycaemic goals. The tier 1 algorithm is the preferred route of therapy for most patients with type 2 diabetes.
Step 1: lifestyle intervention and metformin
Based on the numerous demonstrated short- and long-term benefits that accrue when weight loss and increased levels of activity are achieved and maintained, and the cost-effectiveness of lifestyle interventions when they succeed, the consensus is that lifestyle interventions should be initiated as the first step in treating new-onset type 2 diabetes (Fig. 2). These interventions should be implemented by healthcare professionals with appropriate training, usually registered dietitians experienced in behavioural modification, and be sensitive to ethnic and cultural differences among populations. Moreover, lifestyle interventions to improve glucose, blood pressure and lipid levels, and to promote weight loss or at least avoid weight gain, should remain an underlying theme throughout the management of type 2 diabetes, even after medications are used. For the 10–20% of patients with type 2 diabetes who are not obese or overweight, modification of dietary composition and activity levels may play a supporting role, but medications are still generally required early in the course of diabetes (see Special considerations/patients below).
The authors recognise that for most persons with type 2 diabetes, lifestyle interventions fail to achieve or maintain the metabolic goals, either because of failure to lose weight, weight regain, progressive disease or a combination of factors. Therefore, our consensus is that metformin therapy should be initiated concurrently with lifestyle intervention at diagnosis. Metformin is recommended as the initial pharmacological therapy, in the absence of specific contraindications, for its effect on glycaemia, absence of weight gain or hypoglycaemia, generally low level of side effects, high level of acceptance and relatively low cost. Metformin treatment should be titrated to its maximally effective dose over 1–2 months, as tolerated (see text box: Titration of metformin). Rapid addition of other glucose-lowering medications should be considered in the setting of persistent symptomatic hyperglycaemia.
Step 2: addition of a second medication
If lifestyle intervention and the maximal tolerated dose of metformin fail to achieve or sustain the glycaemic goals, another medication should be added within 2–3 months of the initiation of therapy or at any time when the target HbA1c level is not achieved. Another medication may also be necessary if metformin is contraindicated or not tolerated. The consensus regarding the second medication added to metformin was to choose either insulin or a sulfonylurea (Fig. 2). As discussed above, the HbA1c level will determine in part which agent is selected next, with consideration given to the more effective glycaemia-lowering agent, insulin, for patients with an HbA1c level of >8.5% or with symptoms secondary to hyperglycaemia. Insulin can be initiated with a basal (intermediate- or long-acting) insulin (see Fig. 1 for suggested initial insulin regimens) . However, many newly diagnosed type 2 diabetic patients will usually respond to oral medications, even if symptoms of hyperglycaemia are present .
Step 3: further adjustments
- Tier 2:
less well-validated therapies
In selected clinical settings, this second tier algorithm may be considered. Specifically, when hypoglycaemia is particularly undesirable (for example, in patients who have hazardous jobs), the addition of exenatide or pioglitazone may be considered. Rosiglitazone is not recommended. If promotion of weight loss is a major consideration and the HbA1c level is close to target (<8.0%), exenatide is an option. If these interventions are not effective in achieving target HbA1c, or are not tolerated, addition of a sulfonylurea could be considered. Alternatively, the tier 2 interventions should be stopped and basal insulin started.
Rationale for selecting specific combinations
More than one medication will be necessary for the majority of patients over time. Selection of the individual agents should be made on the basis of their glucose-lowering effectiveness and other characteristics listed in Table 1. However, when adding second antihyperglycaemic medications, the synergy of particular combinations and other interactions should be considered. In general, antihyperglycaemic drugs with different mechanisms of action will have the greatest synergy. Insulin plus metformin  is a particularly effective means of lowering glycaemia while limiting weight gain.
In the setting of severely uncontrolled diabetes with catabolism, defined as fasting plasma glucose levels >13.9 mmol/l (250 mg/dl), random glucose levels consistently >16.7 mmol/l (300 mg/dl), HbA1c >10% or the presence of ketonuria, or as symptomatic diabetes with polyuria, polydipsia and weight loss, insulin therapy in combination with lifestyle intervention is the treatment of choice. Some patients with these characteristics will have unrecognised type 1 diabetes; others will have type 2 diabetes with severe insulin deficiency. Insulin can be titrated rapidly and is associated with the greatest likelihood of returning glucose levels rapidly to target levels. After symptoms are relieved and glucose levels decreased, oral agents can often be added and it may be possible to withdraw insulin, if preferred.
Duality of interest
D. M. Nathan has received a research grant for investigator-initiated research from Sanofi Aventis and support for educational programs from GlaxoSmithKline. J. B. Buse has conducted research and/or served on advisory boards under contract between the University of North Carolina and Amylin, Becton-Dickinson, Bristol-Myers Squibb, Hoffman-LaRoche, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Merck, Novartis, Pfizer and Sanofi Aventis. M. B. Davidson has received research support from Eli Lilly, Merck and Pfizer; has served on advisory boards for Amylin, GlaxoSmithKline, Merck and Sanofi Aventis; and has been on speakers bureaus for Amylin, Eli Lilly, GlaxoSmithKline and Pfizer. E. Ferrannini has received research support from AstraZeneca, Merck Sharpe & Dohme and Novartis and serves on scientific advisory boards for Amylin, AstraZeneca, GlaxoSmithKline, Roche, Merck Sharpe & Dohme, Novartis, Sanofi Aventis, Boehringer Ingelheim and Takeda. R. R. Holman has received research support from Bristol-Myers Squibb, GlaxoSmithKline, Merck Sante, Novo Nordisk, Pfizer and Pronova and has served on advisory boards and/or received honoraria for speaking engagements from Amylin, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis and Sanofi Aventis. R. Sherwin has served on advisory boards for Amylin, AstraZeneca, Boehringer Ingelheim, DiObex, Eli Lilly, Insulet, Merck, MannKind and Novartis. B. Zinman has received research support from GlaxoSmithKline, Merck, Novartis and Novo Nordisk and has been a member of scientific advisory boards and /or received honoraria for speaking engagements from Amylin, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi Aventis and Servier.
- 1.American Diabetes Association. Standards of medical care in diabetes (2008) Diabetes Care 31(Suppl 1):S12–S54Google Scholar
- 3.National Institute for Clinical Excellence (2002) Clinical guidelines for type 2 diabetes mellitus: management of blood glucose. London, NICE. Available from http://www.nice.org.uk/Guidance/CG66
- 4.Diabetes Control and Complications Trial Research Group (1993) The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:978–986Google Scholar
- 13.Abraira C, Duckworth WC, Moritz T (2008) Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab. doi: 10.1111/j.1463-1326.2008.00933.x
- 22.Chobanian AV, Bakris GL, Black HR et al (2003) National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment Of High Blood Pressure; National High blood Pressure Education Program Coordinating committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment Of High Blood Pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRefGoogle Scholar
- 25.National Institutes of Health (1999) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report. National Heart, Lung, and Blood Institute, NIH, Bethesda, MDGoogle Scholar
- 29.Van de Laar FA, Lucassen PL, Akkermans RP et al (2005) Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2:CD003639Google Scholar
- 34.Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2:CD006739Google Scholar
- 40.Rewers M, Hamman RF (1995) Risk factors for non-insulin dependent diabetes. In: Harris M (ed) Diabetes in America, 2nd ed. NIH Publication No. 95–1468. National Institutes of Health, Bethesda, pp 179–220Google Scholar
- 56.Meinert CL, Knatterud GL, Prout TE, Klimt CR (1970) The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II Mortality results. Diabetes 19(Suppl 1):789–830Google Scholar
- 69.Nathan DM, Buse JB, Davidson MB et al (2008) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 51:8–11Google Scholar
- 84.Goldstein B, Feinglos M, Lunceford J, Johnson J, Williams-Herman D (2007) Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979–1987PubMedCrossRefGoogle Scholar